Cólera

27-Deoxyactein is one of the primary cycloartane triterpene glycosides isolated from black cohosh (Actaea/Cimicifuga racemosa) and is considered a key marker compound and active constituent responsible for some of its pharmacological effects relevant to menopausal symptom relief.

8-Prenylnaringenin (8-PN) is a prenylated flavonoid from hops (Humulus lupulus) considered the most potent phytoestrogen identified to date. RCT pilot data support its use for menopausal hot flashes and vasomotor symptoms. It binds estrogen receptors with greater affinity than other plant phytoestrogens.

Agnuside is the primary iridoid glycoside marker compound and active constituent of Vitex agnus-castus (chaste tree), which has demonstrated clinical efficacy for menopausal symptoms in multiple RCTs. Agnuside-standardized extracts of VAC are the form used in most clinical studies.

Pimenta dioica leaf extracts have been studied for oestrogenic and anti-oestrogenic activity in cell-based assays. Research shows allspice compounds bind to both ERα and ERβ oestrogen receptors, with a 2018 study concluding compounds from P. dioica have oestrogenic, anti-oestrogenic, and cytotoxic effects. Costa Rican women use allspice traditionally for menopausal symptoms.

Ashwagandha (Withania somnifera) has been studied in RCTs specifically for perimenopausal and postmenopausal women. A double-blind RCT using 300 mg twice daily for 8 weeks improved overall climacteric symptom scores in perimenopausal women. A 2025 RCT demonstrated dose-dependent reductions in menopausal symptoms, vascular dysfunction, and bone resorption markers in postmenopausal women.

Multiple small clinical trials show pollen extracts reduce hot flush frequency, improve sleep, mood, and overall quality of life in peri- and postmenopausal women. A RCT of the pollen-based product Femal found 65% of treated women reported reduction in hot flushes versus 38% on placebo. The evidence is preliminary but consistent.

Black cohosh (Cimicifuga/Actaea racemosa) is one of the most extensively studied botanicals for menopause. A 2023 meta-analysis of 22 studies found it potentially beneficial for overall menopausal symptoms, particularly hot flashes. A 2017 systematic review of 47 RCTs (n=8,326) found it more effective than placebo for vasomotor symptoms, though not significantly better than transdermal estradiol.

The NIH ODS identifies low boron intake as specifically impacting postmenopausal women, who experience reduced estrogen alongside altered calcium, vitamin D, and osteocalcin metabolism. Boron repletion in postmenopausal women raised 17β-estradiol and improved calcium retention in the Nielsen 1987 FASEB study. Boron may partially mimic or support estrogen's role in bone mineral conservation during menopause.

B. falcatum is a principal ingredient in classical TCM formulas used for climacteric symptoms including Xiao Yao San and Jia Wei Xiao Yao San. A clinical trial using a B. falcatum-dominant decoction showed efficacy for both vasomotor and psychological menopausal symptoms. Scientific studies have also explored its role in preventing postmenopausal bone loss.

Calcium is the primary mineral for bone structural integrity and is directly relevant to postmenopausal osteoporosis. Postmenopausal women exhibit heightened susceptibility to calcium deficiency, and supplementation combined with vitamin D is considered non-negotiable by multiple clinical guidelines for menopausal bone health.

Chaste Tree (Vitex agnus-castus) is one of the most widely used botanical agents for women's health. It modulates dopaminergic, phytoestrogenic, and serotonergic pathways relevant to menopausal symptoms. A 2019 RCT found significant reduction in menopausal symptom frequency and severity vs. placebo. German Commission E approved it for menstrual cycle irregularities common in perimenopause.

Daidzein is a key soy isoflavone and the direct metabolic precursor to equol, a more potent phytoestrogen. A meta-analysis confirmed that equol producers who convert daidzein to equol achieve significantly better hot flash reductions. Daidzein-containing soy isoflavone preparations are used in RCTs for menopausal vasomotor symptom management.

Daidzin, as a principal soy isoflavone, has been clinically evaluated for menopausal symptom relief. Clinical trials demonstrate modest benefits on vasomotor symptoms, with effects dependent on equol-producing status. Evidence also supports modest benefits on bone density and lipid profiles in postmenopausal women.

DHA is an essential omega-3 fatty acid supporting cardiovascular and cognitive health during menopause. The cognitive decline and mood disturbances associated with menopause may be partially addressable with DHA supplementation. Combined with EPA, DHA-containing omega-3 supplements are supported for postmenopausal cardiovascular protection per multiple systematic reviews.

Intravaginal DHEA (prasterone) is FDA-approved for dyspareunia due to menopause and has been shown in four placebo-controlled RCTs to significantly improve genitourinary syndrome of menopause symptoms. Oral DHEA shows uncertain evidence for broader menopausal symptom relief including quality of life, though it may slightly improve sexual function. Effects on vasomotor symptoms are minimal.

DIM (3,3'-diindolylmethane) is a metabolite of indole-3-carbinol formed during digestion of cruciferous vegetables. It modulates estrogen metabolism by promoting conversion of potent estrogens to weaker 2-OHE1 metabolites, which is considered beneficial during the hormonal shifts of menopause. It is a recognized menopause-related ingredient in multiple databases.

EPA is an omega-3 fatty acid with documented cardiovascular and anti-inflammatory benefits relevant to postmenopausal health. EPA-rich omega-3 formulations consistently lower triglycerides and systemic inflammatory markers in the menopausal context per a 2025 comprehensive systematic review. EPA also has emerging evidence for mood support.

Equol is a metabolite of the soy isoflavone daidzein, produced by intestinal bacteria, and is considered a more potent phytoestrogen than its parent compound. A meta-analysis of RCTs confirmed significant benefit of equol supplementation for reducing hot flash scores in postmenopausal women, particularly among non-equol-producers who cannot synthesize it endogenously.

Multiple RCTs demonstrate that standardized fenugreek seed extract significantly alleviates a broad spectrum of menopausal symptoms including hot flashes, night sweats, vaginal dryness, depressive mood, sleep disturbances, and leg/joint pain. Effects are linked to phytoestrogenic compounds raising circulating estradiol.

Animal studies show fisetin supports hormonal balance, reduces ovarian oxidative stress, and may ease menopause-related symptoms through senolytic clearance of ovarian senescent cells. A 2026 Johns Hopkins review documents its preclinical relevance to menopausal transition.

Flaxseed is a rich source of plant lignans converted by gut bacteria to phytoestrogenic enterolactone and enterodiol. Mixed but increasingly positive clinical trial data support its use for mild menopausal symptoms. A 2024 study found flaxseed effective for hot flashes, night sweats, and sleep difficulties.

Gamma oryzanol has documented clinical use for menopausal symptom relief, particularly in Japan. Clinical trials show reductions in vasomotor symptoms, mood changes, and lipid abnormalities common in menopause. Its mechanism involves modulation of the hypothalamic-pituitary axis, reducing LH release and stimulating endorphin production.

Genistein is the primary active isoflavone in soy, acting as a phytoestrogen via preferential ERβ binding. Clinical RCTs show genistein-predominant preparations most effectively reduce menopausal hot flash frequency. A 2025 PMC review specifically identifies genistein and daidzein as natural phytoestrogens with potential HRT applications.

Genistin is the glucoside form of genistein found in soy and red clover, hydrolyzed in the gut to the active phytoestrogen genistein. It is listed as a recognized menopause-related ingredient in multiple authoritative databases and its clinical effects are mediated through conversion to genistein, which reduces hot flash frequency in menopausal women.

Geranium aromatherapy has been used clinically to reduce depression in postmenopausal women and to modulate salivary estrogen levels. It is classified as phyto-estrogenic in some traditional systems and is used for hot flushes, mood swings, and hormonal balance during menopause.

Korean red ginseng is the most studied form for menopause; a 2024 review found it may improve overall menopausal symptoms and quality of life. It appears to benefit mood and sleep but has not consistently reduced vasomotor symptoms (hot flashes) in RCTs. It is also traditionally used in East Asian medicine for reproductive health and vitality in older women.

GLA-containing oils (evening primrose oil) have clinical evidence for relieving several menopausal symptoms including hot flashes, night sweats, and psychological symptoms. Multiple controlled trials support modest but statistically significant benefits. GLA's eicosanoid-modulating effects are hypothesized to underlie these benefits.

Glycitin is one of three primary soy isoflavones (alongside genistin and daidzin) studied for menopausal symptom management. Soy isoflavone preparations containing glycitin have demonstrated benefits for hot flashes, bone density, oxidative stress, and lipid abnormalities in postmenopausal women across multiple clinical trials and meta-analyses. Glycitin's contribution is through its phytoestrogenic aglycone glycitein.

A randomized double-blind pilot study examined grape seed proanthocyanidin extract (GSPE) in middle-aged women with menopausal symptoms, assessing body composition and cardiovascular parameters. Resveratrol in a long-term RCT in postmenopausal women improved chronic pain, somatic menopausal symptoms, and circulatory function. GSE supplementation also improved blood pressure and endothelial function specifically in postmenopausal women.

HMR's conversion to the phytoestrogen enterolactone supports its study as a natural menopause support agent. Human pharmacokinetic data confirm rapid HMR absorption and ENL production in postmenopausal women. Clinical data show reductions in hot flash frequency and shifts in estrogen metabolite ratios consistent with improved menopausal hormonal profiles.

HMR Lignan (7-hydroxymatairesinol, HMR) is a plant lignan from Norway spruce knots that is efficiently converted by gut bacteria to enterolactone, a phytoestrogen. It is a standardized, patented ingredient (HMRlignan™) recognized in multiple menopausal supplement formulations and ingredient databases for its phytoestrogenic activity.

Hops (Humulus lupulus) contain 8-prenylnaringenin (8-PN), identified as the most potent phytoestrogen discovered in plants. Clinical and in vitro studies support hops for menopausal symptom relief including hot flashes, sleep disturbances, vaginal dryness, and fatigue. The European Food Safety Authority has reviewed a health claim for hops for menopausal symptom relief.

Vaginal HA formulations have demonstrated clinical efficacy in reducing genitourinary syndrome of menopause (GSM) symptoms — including dryness, burning, and dyspareunia — in multiple RCTs. A 2026 systematic review and meta-analysis confirmed HA as a safe, effective non-hormonal option with moderate-quality evidence. HA's strong water-binding properties restore mucosal hydration and viscoelasticity compromised by postmenopausal hypoestrogenism.

Icariin is the primary prenylflavonoid from Epimedium (horny goat weed/barrenwort) that acts as a phytoestrogen via ERβ binding and a bone-anabolic agent. A clinical study with icaritin (its demethylated metabolite) in postmenopausal women demonstrated bone mineral density preservation. It is recognized in multiple authoritative menopause ingredient databases.

Ipriflavone has been studied in numerous RCTs for prevention of postmenopausal bone loss. A 2020 systematic review and meta-analysis of RCTs confirmed it significantly increases BMD and inhibits bone resorption markers in postmenopausal women with osteopenia or osteoporosis. It does not possess intrinsic estrogenic activity but potentiates estrogen's bone-protective effects. The large Ipriflavone Multicenter European Fracture Study (IMEFS, JAMA 2001) did not replicate BMD gains, leaving overall evidence mixed.

Isoflavones from soy and red clover are the most extensively studied phytoestrogens for menopausal symptom relief. Multiple systematic reviews and meta-analyses support their modest efficacy for reducing hot flash frequency and severity. Genistein- and equol-based formulations show the strongest evidence.

Kudzu (Pueraria lobata/P. montana) root contains puerarin and daidzein, phytoestrogens studied for menopausal benefits including bone protection and cardiovascular effects. Authoritative botanical medicine reviews list kudzu as a phytoestrogen-containing plant with estrogenic activity for menopausal symptom relief.

Licorice root (Glycyrrhiza glabra and related species) contains glabridin and liquiritigenin, phytoestrogens that have demonstrated estrogenic activity via ERβ in cell assays. The Iranian systematic review of 19 herbal RCTs included licorice among herbs that alleviate menopausal hot flashes. Estrogenic licorice extracts are commonly included in botanical menopause formulas.

Lignans are phytoestrogens concentrated in flaxseed, sesame, and whole grains that are converted by gut bacteria to enterolactone and enterodiol. These enterolignans act as weak estrogen receptor agonists and antagonists. Multiple clinical reviews support lignans for menopausal symptom reduction, particularly in flaxseed preparations.

Maca (Lepidium meyenii), a root native to Peru, has been used traditionally for energy, libido, and hormonal balance. Clinical evidence indicates maca improves psychological symptoms (anxiety, depression) and sexual dysfunction in postmenopausal women without directly affecting estrogen or androgen levels. A 2024 review found it may improve menopausal symptoms and quality of life.

Magnesium is involved in over 300 biochemical reactions and is particularly relevant during menopause for sleep quality, bone health, and mood regulation. NIH data show it is deficient in the majority of women. A 2025 systematic review identified magnesium as critical for counteracting the heightened inflammatory and cardiovascular burden of menopause.

Magnolia bark is one of the most clinically studied herbal interventions for menopausal psycho-affective symptoms. A multicenter RCT in 634 menopausal women showed the magnolia-containing supplement significantly improved insomnia, irritability, anxiety, depressed mood, and libido versus the control formula. A 24-week trial in 89 women and a study in 180 women add further clinical support.

Melatonin levels decline with aging and during menopause, contributing to the sleep disturbances that affect up to 60% of menopausal women. Multiple RCTs support melatonin supplementation for improving sleep quality in postmenopausal women. It is listed as a recognized menopausal ingredient in authoritative ingredient databases.

A 2026 RCT found that 12 weeks of OLE supplementation significantly improved postmenopausal symptoms as assessed by validated instruments. The same trial also showed reductions in pentosidine (AGE marker) and triglycerides in postmenopausal women. Separately, a 12-month RCT showed increased osteocalcin, relevant to post-menopausal bone loss.

Omega-3 fatty acids (EPA and DHA), primarily from fish or algal oil, have demonstrated cardioprotective and anti-inflammatory benefits particularly relevant to the elevated cardiovascular risk of postmenopause. Some evidence supports mood benefits. However, they are not effective for reducing hot flashes in large RCTs.

Sea buckthorn oil (omega-7) has been studied for menopausal symptoms—particularly vaginal atrophy and dry eyes—in randomized controlled trials. The Larmo et al. 2014 RCT in postmenopausal women demonstrated improvement in vaginal epithelial integrity. Omega-7's role in supporting mucous membrane integrity makes it relevant to several estrogen-decline-driven symptoms.

Gamma-oryzanol from Oryza sativa rice bran is approved in Japan for menopausal (climacteric) symptoms including hot flashes, sweating, and mood changes. Multiple clinical trials demonstrate reductions in Kupperman index scores in perimenopausal and postmenopausal women.

Paeonia lactiflora is used as a component of Chinese herbal formulas for menopausal syndrome including hot flashes, mood disturbance, and hormonal fluctuation. Preclinical and review-level evidence supports its estrogenic and neuroendocrine modulatory activities; clinical review data suggest efficacy comparable to hormone therapy.

Phytoestrogens are plant-derived compounds (including isoflavones, lignans, and coumestans) that bind estrogen receptors and mimic weak estrogenic activity. Diets enriched with phytoestrogen-containing foods are repeatedly linked to reduced vasomotor symptom severity and bone integrity preservation in menopause. Multiple classes have been studied in RCTs.

A double-blind RCT in 200 peri-menopausal women treated with Pycnogenol 200 mg/day showed significant alleviation of climacteric symptoms as measured by the Women's Health Questionnaire. A 2013 RCT (n=170) using low-dose PBE also reduced menopausal symptoms. This is listed as a clinical indication in multiple authoritative reviews.

Two RDP trials in peri-menopausal women demonstrate Pycnogenol significantly reduces menopausal symptoms including hot flashes, night sweats, mood swings, vaginal dryness, and sleep disturbance. A 200-woman RCT using the Women's Health Questionnaire showed significant improvement vs. placebo at 6 months. Benefit appears independent of hormonal activity.

A 2023 systematic review and meta-analysis found pomegranate significantly improved hot flash severity, menopause symptom scores, and reduced FSH levels in peri- and postmenopausal women. Pomegranate seed oil was evaluated in a placebo-controlled RCT for menopausal symptoms. Phytoestrogens in pomegranate seed oil contribute to the proposed estrogenic mechanism.

Pregnenolone is the biochemical precursor to estrogen, progesterone, and testosterone, all of which decline during menopause. Clinical interest is formalized in an active MGH RCT investigating pregnenolone for menopausal depression. Its downstream hormone-replenishing potential and direct neurosteroid actions may address cognitive and mood symptoms of menopause.

Progesterone is a core component of menopausal hormone therapy (MHT), required to protect the uterus from estrogen-induced endometrial hyperplasia and cancer. It also improves hot flashes, sleep, and mood symptoms. Oral micronized progesterone is preferred over synthetic progestins for its superior cardiovascular, thromboembolic, and breast safety profile.

Puerarin is the primary bioactive isoflavone glycoside in kudzu root (Pueraria lobata). It acts as a phytoestrogen via ERβ binding and has been studied for cardiovascular and bone protective effects in postmenopausal settings. Puerarin is listed as a menopause-relevant ingredient in multiple authoritative databases.

Pumpkin seed oil is a documented source of phytoestrogens (lignans) that may modulate estrogenic activity post-menopause. Human and animal studies show that PSO supplementation improves lipid profiles, arterial hemodynamics, and overactive-bladder symptoms—all common concerns in postmenopausal women. Clinical trial data from postmenopausal cohorts are available.

Red clover (Trifolium pratense) contains isoflavones (biochanin A, formononetin, daidzein, genistein) that act as phytoestrogens via estrogen receptor-beta binding. A 2021 meta-analysis of 8 RCTs showed a statistically significant reduction of ~1.73 hot flashes/day vs. placebo. A 2024 RCT of 75 postmenopausal women found significant improvements in Menopause Rating Scale scores at 3 and 6 months.

Rehmannia is extensively used in TCM menopausal formulas, and modern network pharmacology has identified its bioactive compounds as targeting menopause-linked protein pathways. Clinical pharmacological evidence supports its inclusion in Liuwei Dihuang Wan and Zhi Bai Di Huang Wan for menopausal syndrome. A 2025 PMC network pharmacology study specifically mapped RG's compounds to menopausal condition targets.

Rehmannia glutinosa is the principal ingredient in Liu Wei Di Huang Wan, one of the most prescribed TCM formulas for menopausal symptoms. Network pharmacology confirms active compounds interact with menopause-relevant hormonal pathways. Some studies confirm effectiveness of rehmannia-containing formulas for night sweats and hormone disruptions.

Resveratrol has been studied across multiple menopausal endpoints in human RCTs. The 24-month RESHAW trial found improvements in cognitive function, cerebrovascular reactivity, bone mineral density, pain, and well-being in 125 postmenopausal women taking 75 mg twice daily. Smaller trials support benefits for vasomotor symptoms, sleep, and mood. A systematic review across nearly 200 clinical trials recognizes menopause symptoms as one of resveratrol's studied indications.

ERr 731 (standardized Rheum rhaponticum root extract) has robust RCT and long-term clinical study evidence for reducing the full spectrum of menopausal symptoms, including vasomotor, psychological, and urogenital domains, via selective ERβ agonism.

Rosa damascena oral extract significantly reduced depression, anxiety, and stress symptoms in menopausal women in a 2025 triple-blind RCT (n=82). A separate triple-blind RCT (n=82) found Rosa damascena extract positively affected sexual function in menopausal women including desire, arousal, lubrication, and orgasm. These are the most clinically rigorous data for rose in menopausal symptom management.

Several RCTs and observational studies show RJ supplementation reduces overall menopausal symptom burden (Kupperman index, MENQOL scores), including hot flashes, mood changes, vaginal dryness, and sleep disturbance. Phytoestrogenic activity via estrogen receptor binding is the primary proposed mechanism.

Saffron (Crocus sativus) has been studied in RCTs for perimenopausal women and shows significant benefits for mood, anxiety, sleep, and overall menopausal symptom burden. A double-blind RCT of 86 perimenopausal women using 28 mg/day of standardized saffron extract for 12 weeks found significant improvements in psychological and menopausal symptom scores.

Sage (Salvia officinalis) has traditional use across Europe for reducing night sweats and hot flashes during menopause. A Swiss open-label clinical trial found a daily sage tablet reduced hot flash frequency by 64% over 8 weeks in women with at least 5 hot flashes per day. Mechanistic studies point to anticholinergic and estrogenic activities.

A 2016 randomized, double-blind, placebo-controlled trial (n=36) demonstrated schisandra extract significantly reduced overall menopausal symptom burden (Kupperman Index, Menopause Rating Scale) versus placebo over 6–12 weeks. ScienceDirect lists menopause among conditions for which clinical research indicates schisandra may be beneficial. TCM has used the herb for menopausal symptoms for centuries.

A mouse model of VCD-induced ovarian failure showed Schisandrae Fructus reduces menopausal symptoms. A 2020 ScienceDirect review notes schisandrins regulate hormonal balance and alleviate menopause symptoms. Human clinical data are limited, but the mechanistic and animal evidence basis is documented.

SDG is a phytoestrogen that binds estrogen receptors and has been studied for its effects on estrogen-deficiency symptoms of menopause, including postmenopausal osteoporosis and bone loss. Clinical evidence confirms SDG can increase bone mass and serum calcium and control bone loss in postmenopausal women. SDG and its metabolites have also been examined in the context of menopause-related disease risk reduction including cardiovascular and hormone-sensitive cancers.

Clinical evidence includes a 5-week study in 24 postmenopausal women showing that 50 mg/day sesame powder improved hormone status, antioxidant levels, and blood fat levels. Sesame lignans are converted to enterolactone (a weak phytoestrogen), offering potential broad menopausal support. Evidence is modest but published in peer-reviewed literature.

Soy isoflavones are extensively studied for managing the menopausal transition. Clinical evidence supports reductions in hot flash frequency and severity, modest improvements in vaginal symptoms, and possible skeletal and cardiovascular benefits in postmenopausal women. Mechanistically, isoflavones act as phytoestrogens via estrogen receptor modulation.

Soy isoflavones (genistein, daidzein, glycitein) are phytoestrogens shown in multiple RCTs and meta-analyses to modestly reduce hot flash frequency and severity in menopausal women. A 2012 meta-analysis found extracted/synthesized soy isoflavones significantly reduced hot flash frequency. Evidence for bone health is also present, though less conclusive.

Soy isoflavones have been extensively studied as an alternative to menopausal hormone therapy for vasomotor and other menopausal symptoms. Clinical evidence supports modest reductions in hot flash frequency and severity; effects on other menopausal symptoms such as depression, bone loss, and vaginal dryness have also been studied. Meta-analytic evidence supports isoflavones as effective in improving BMD and reducing hot flashes in postmenopausal women.

St. John's wort (Hypericum perforatum) is primarily evidence-based for mild-to-moderate depression and has demonstrated benefit for mood-related menopausal symptoms. Multiple sources indicate it improves mood disorders associated with menopausal transition. It has been studied in combination with black cohosh and Vitex agnus-castus for comprehensive menopausal symptom relief.

Succinate-based dietary supplements have been evaluated in several RCTs in perimenopausal and postmenopausal women, demonstrating improvements across vasomotor, psychological, and somatic symptom domains. Effects include reduced anxiety, improved body weight markers, and increased estradiol. A 2024 Advances in Therapy trial further evaluated Amberen combined with B vitamins in perimenopause.

Multiple RCTs have specifically tested tribulus in postmenopausal women with sexual dysfunction, demonstrating significant improvements in sexual desire, arousal, and satisfaction vs. placebo. A systematic review identified five parallel-design RCTs enrolling 279 women, though overall evidence certainty was rated very low.

Valerian root (Valeriana officinalis) contains phytoestrogenic and GABAergic constituents and has been studied for menopause-related sleep disturbances and hot flashes. A randomized double-blind clinical trial of 100 postmenopausal women with insomnia found 30% experienced improved sleep quality with valerian vs. 4% on placebo. Evidence for hot flash reduction is also present but mixed.

Vitamin B12 is required for neurological function, DNA synthesis, and homocysteine regulation. Postmenopausal women face elevated risk of B12 deficiency due to reduced gastric acid and intrinsic factor secretion with aging, contributing to neurological symptoms, fatigue, and cognitive decline overlapping with menopause. It is listed in menopausal nutritional support protocols.

Vitamin B6 (pyridoxine) plays roles in neurotransmitter synthesis (serotonin, GABA, dopamine) and hormonal metabolism relevant to menopausal mood disturbances. It is listed in authoritative menopause ingredient databases and British Menopause Society nutritional guidance for perimenopausal mood support, depression, and PMS-related symptoms that overlap with menopausal transition.

Vitamin D is critical for calcium absorption and bone health, making it directly relevant to postmenopausal osteoporosis prevention. A comprehensive 2025 systematic review confirmed that vitamin D and calcium together yield clinically meaningful benefits in postmenopausal osteoporosis management. Postmenopausal women are highly susceptible to vitamin D deficiency.

Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D, directly relevant to postmenopausal bone health and osteoporosis prevention. A 2025 systematic review confirmed its benefits alongside calcium for postmenopausal osteoporosis management. Postmenopausal women are specifically identified as a population at high risk for vitamin D deficiency.

Vitamin E (alpha-tocopherol) has been studied in small RCTs for menopausal hot flash reduction. One RCT of breast cancer survivors showed significant hot flash reductions versus placebo. GoodRx (2025) notes there is at best a mild effect for hot flashes, while high doses carry bleeding risk.

Vitex agnus-castus (chaste tree) has a long history of use for gynecological conditions, including early menopausal symptoms. A 2019 randomized double-blind study found it significantly reduced menopausal symptom frequency and severity vs. placebo. Mechanistically, it modulates dopaminergic, phytoestrogenic, opioidergic, and serotonergic pathways relevant to menopausal neurobiology.

Alfalfa (Medicago sativa) contains coumestans (coumestrol) and isoflavones that act as phytoestrogens. It has traditional use in North American and Ayurvedic medicine for menopausal symptoms. It is listed in multiple authoritative menopause ingredient databases and referenced in the Iranian systematic review of herbs for menopausal hot flashes.

Anemarrhena is a core herb in TCM management of climacteric syndrome, appearing in classic formulas for menopausal hot flashes, night sweats, insomnia, and irregular periods. It is documented in multiple classical Chinese medical texts and remains prescribed across East Asian clinical systems for these indications.

Asparagus racemosus (Shatavari) is a foundational Ayurvedic herb used for thousands of years for women's reproductive health and menopausal symptoms. A 2025 double-blind RCT demonstrated dose-dependent reductions in menopausal symptoms, vascular dysfunction, and bone resorption in postmenopausal women taking shatavari extract.

Barrenwort (Epimedium species, also known as horny goat weed or Yin Yang Huo) has a 2,000-year history in TCM as a tonic for kidney deficiency and menopausal symptoms. Its primary compound icariin acts as a phytoestrogen and phosphodiesterase-5 inhibitor. It is listed in multiple authoritative menopause ingredient databases.

Borage oil has a documented traditional use for menopausal symptoms, attributed to GLA's ability to modulate prostaglandin synthesis and support hormonal balance. A clinical study in postmenopausal women with hypertension showed short-term benefit on blood pressure, but robust RCT evidence specifically for menopausal symptom relief is lacking.

Borage oil has been traditionally promoted and widely used for menopausal symptoms. Clinical evidence is indirect, primarily from trials of structurally similar evening primrose oil (also a GLA source), with a 6-month RCT finding no benefit of EPO over placebo for vasomotor symptoms. No specific borage oil RCT for menopause has been identified in peer-reviewed literature.

Chamomile (Matricaria chamomilla) has traditional use in European herbalism for anxiety, insomnia, and stress — all prominent menopausal symptoms. A combination RCT of fennel, chamomile, and saffron found improvements in vaginal atrophy and menopausal symptoms. Chamomile is included in menopausal botanical formulas across multiple traditional systems.

Clary sage (Salvia sclarea) has traditional use in European herbalism for menstrual and menopausal complaints. Its essential oil contains sclareol, a diterpene with estrogenic activity. It is used in aromatherapy and orally for hot flashes, and is listed in multiple menopausal ingredient databases.

Damiana (Turnera diffusa) has traditional use in Mexican and Mesoamerican folk medicine as an aphrodisiac and female tonic for menopausal libido loss, hot flashes, and mood disturbances. It contains weak phytoestrogenic compounds and aromatase-inhibiting flavonoids. It is listed in multiple menopause ingredient databases.

Dioscorea (wild yam species) has extensive traditional use in TCM and indigenous American medicine for menopausal symptoms, primarily via its diosgenin content. However, the human body cannot convert diosgenin to progesterone or estrogen, and clinical RCT evidence for menopausal symptom relief is negative for topical preparations.

Dong quai (Angelica sinensis) has been a cornerstone of Traditional Chinese Medicine for women's health, including menopausal complaints, for over 2,000 years. It is known as 'female ginseng' in TCM. However, clinical trial evidence as a monotherapy has not confirmed estrogenic effects or significant reduction of hot flashes versus placebo.

Dong quai root (Angelica sinensis) is a classic TCM herb used for over 2,000 years as a 'female tonic' for menstrual disorders and menopausal complaints. Despite widespread traditional use, RCT evidence as a monotherapy has not confirmed significant reduction of menopausal hot flashes or estrogenic effects in postmenopausal women.

Evening primrose oil (EPO, Oenothera biennis) is widely used traditionally for menopausal hot flashes and hormonal symptoms. However, systematic clinical review evidence is largely negative: an RCT (n=56) found no significant difference from placebo for hot flashes, and multiple authoritative reviews conclude it does not effectively alleviate menopausal vasomotor symptoms.

Fennel (Foeniculum vulgare) has traditional use in Mediterranean herbalism for menopausal symptoms. A combination RCT of fennel, chamomile, and saffron found improvements in vaginal atrophy and menopausal symptoms. Fennel contains phytoestrogenic compounds (anethole, phytoestrogens) and is included in the Iranian hot flash systematic review.

Ginkgo biloba is traditionally used for cognitive support and circulation enhancement, addressing brain fog, memory decline, and mood disturbances common in menopause. Listed in botanical reviews as used for menopausal cognitive and mood symptoms. Evidence is primarily for general cognitive and circulatory benefits with indirect application to menopause.

Horny goat weed (Epimedium species) is a traditional Chinese herbal medicine with over 2,000 years of use for reproductive and menopausal conditions. Its active constituent icariin acts as a phytoestrogen and bone-protective agent. It is recognized in multiple menopause ingredient databases and supported by in vitro and animal mechanistic evidence.

Kava (Piper methysticum) is traditionally used by Pacific Island cultures and has been investigated for menopausal anxiety and mood symptoms. Some German clinical studies found benefit for anxiety components of menopause. However, it is associated with hepatotoxicity risk and has been removed from markets in several countries, making its use controversial.

Lemon balm (Melissa officinalis) has traditional use in European herbal medicine for anxiety, insomnia, and mood disturbances — a major symptom cluster in menopausal transition. A clinical study found standardized lemon balm significantly reduced anxiety and insomnia in adults. It is used in menopausal symptom formulas and listed in menopause ingredient databases.

Motherwort (Leonurus cardiaca) has a long history in European and Chinese herbal medicine for gynecological conditions, including menopausal heart palpitations, hot flashes, and nervous tension. It is listed among botanicals commonly used for menopause in authoritative botanical medicine reviews, though not well-studied in menopause-specific RCTs.

A. vulgaris is documented for treatment of menopausal symptoms in the European Pharmacopoeia (as a homeopathic preparation) and in TCM tradition. The plant's estrogenic activity, confirmed in pharmacological studies, provides mechanistic support. Adams et al. (Chinese Medicine 2012) specifically reviewed mugwort for menopause. Moxibustion is clinically used for hot flashes. No oral supplementation RCTs for menopause exist.

Passionflower (Passiflora incarnata) has traditional use in European and North American herbal medicine for anxiety, insomnia, and nervous tension — all prominent menopausal complaints. It modulates GABA-A receptors. The Iranian hot flash systematic review mentioned it as potentially alleviating menopausal side effects, and it appears in multiple menopausal botanical formulas.

In TCM, P. amurense (Huang Bai) is used for menopausal symptoms including hot flashes, night sweats, and restlessness, classified as 'bone-steaming hectic fever from yin deficiency.' This is a well-documented traditional indication. The Relora blend (Magnolia + P. amurense) has been studied for stress and anxiety in premenopausal women, providing indirect clinical context.

Ligustrum lucidum has long been used in TCM for menopausal complaints, particularly premature menopause, attributed to its yin-nourishing effects on the liver and kidneys. The Erzhi Pill formula containing FLL is documented in Taiwanese and Chinese clinical application for menopausal symptoms. No standalone human RCTs of ligustrum for menopause exist.

Rhodiola rosea is an adaptogenic herb with traditional use in Scandinavia and Russia for stress, fatigue, and mood — symptoms prominent in menopausal transition. Clinical evidence for general adaptogenic effects is well-supported, and it is increasingly recommended for menopausal mood and energy symptoms. Menopause-specific RCTs are limited.

Sarsaparilla has traditional use as a hormone-balancing tonic for menopausal symptoms, attributed to its steroidal saponins which are described in some sources as phytoestrogenic. No human clinical trials have been conducted, and direct estrogenic activity in humans has not been confirmed.

Suma is traditionally used in South American folk medicine to alleviate menopausal symptoms such as hot flashes and mood changes, supported by its documented ability to modulate estradiol and progesterone levels in animal studies. No human clinical trials have confirmed efficacy for menopausal symptoms.

Wild yam (Dioscorea villosa) is widely used in traditional Chinese and indigenous American medicine for menopausal symptoms, primarily via topical creams purported to act as 'natural progesterone.' However, the human body cannot convert diosgenin (wild yam's main compound) to progesterone, and one RCT found no difference from placebo for symptom improvement.

Wood betony is documented in traditional herbal practice for menopausal complaints, particularly restless insomnia and depression associated with stagnant or congested uterine conditions. This is a practitioner-based traditional use without clinical trial support.

Yarrow is traditionally used in several systems for menopausal complaints, and its documented in vitro estrogenic activity provides a plausible mechanistic basis. European and Middle Eastern folk use mentions it for female hormonal regulation including menopausal symptoms, but no specific human clinical trials on menopausal endpoints have been published.